純合子遺傳性高膽固醇症市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類別、給藥途徑、技術、分銷管道、地區和競爭格局分類，2021-2031年

全球純合子遺傳性性高膽固醇症(HoFH) 市場預計將從 2025 年的 9,478 萬美元成長到 2031 年的 1.1101 億美元，複合年成長率為 2.67%。

純合子家族性高膽固醇血症（HoFH）是嚴重的遺傳性疾病，其特徵是出生時低密度脂蛋白膽固醇（LDL-C）水平極高，需要積極治療以預防早期心血管事件。市場成長主要由創新藥物的推出所驅動，例如ANGPTL3抑制劑，這些藥物為對傳統降血脂療法無反應的患者提供了有效的治療方案。此外，將先進的基因篩檢納入常規臨床實踐也是關鍵促進因素，這有助於早期干預並促進這些特效藥的應用。

然而，該市場在精準識別目標患者群體方面面臨重大挑戰。臨床症狀的多樣性以及缺乏廣泛的專業檢測，導致漏診率居高不下，成為一大障礙。根據世界心臟聯盟預測，到2024年，全球僅有不到5%的純合子家族性高膽固醇血症（HoFH）患者能夠獲得準確及時的診斷。如此巨大的診斷缺口嚴重限制了可用治療方法的範圍，也是市場進一步擴張的主要障礙。

市場促進因素

隨著製藥公司不斷推出先進機制以克服傳統他汀類藥物療法的局限性，新型降LDL生物製藥和小分子化合物的研發成為市場成長的主要驅動力。包括第三代PCSK9抑制劑和mRNA治療方法在內的新治療方法正在快速推進臨床試驗，以應對難治性高膽固醇血症患者的嚴重膽固醇負擔。例如，LIB Therapeutics公司於2025年1月發表了一項評估新型藥物lerodarcibep治療66例遺傳性高膽固醇症（HoFH）患者療效的3期臨床試驗結果。這些創新不僅拓展了可用的治療選擇，還提高了給藥的便利性，從而增強了患者終身治療的依從性。

同時，孤兒藥認定和監管激勵措施正顯著促進該領域的研發投入。監管機構擴大授予藥物特殊地位，以降低研發成本並提供市場獨佔權，鼓勵生物技術公司將目光投向心血管疾病極為罕見的疾病，儘管患者數量有限。根據 Fierce Pharma 2026 年 1 月的數據顯示，2025 年 FDA核准的所有新藥中，57% 被認定為孤兒藥，這凸顯了這些獎勵對該行業的強大吸引力。鑑於患者數量極少，此類監管支持至關重要。根據 BioSpace 2025 年 1 月的報告，該疾病在全球影響著約三十萬分之一的人口。這些獎勵確保了足夠的商業性利益，從而能夠涵蓋開發根治性治療方法的高成本。

市場挑戰

準確識別目標患者群體的極大困難是全球遺傳性高膽固醇症(HoFH) 市場成長的主要障礙。這種普遍存在的漏診現象造成了嚴重的瓶頸，因為被醫療系統忽視的患者無法獲得新的治療方案。因此，目標市場規模被人為壓低，阻礙了製造商充分實現諸如 ANGPTL3 抑制劑等先進治療方法的商業性價值。這種遺傳疾病的估計盛行率與實際確診患者數量之間的巨大差異，意味著相關人員損失了大量的商機。

這項挑戰直接源自於檢測方案的缺陷，導致大量病例漏診。根據家庭心臟基金會2025年的報告，美國9至21歲的兒童中僅有11%有血脂篩檢紀錄。如此低的篩檢率表明，大多數患者在最佳干預時機被漏診，因此無法獲得藥物治療。這種對患者群體認知上的系統性不足嚴重阻礙了市場擴張，並限制了現有治療方法的覆蓋範圍。

市場趨勢

將生物製藥的適應症擴展至兒童患者群體，從根本上擴大了目標市場，使得在疾病進展的早期階段進行干預成為可能。核准用於較年輕的年齡層，使製藥公司能夠在預防不可逆血管損傷的關鍵時期接觸到患者，而不再局限於治療成人晚期疾病。 ANGPTL3抑制劑適應症的擴展便是此轉變的例證，其適應症現已涵蓋先前缺乏有效藥物治療方案的嬰幼兒。例如，《當代兒科學》雜誌在2025年9月報道，美國FDA核准ANGPTL3抑制劑evinacumab用於治療1至5歲以下患有遺傳性高三酸甘油脂血症（HoFH）的兒童。這為這極為罕見的患者族群樹立了新的治療標準。

同時，臨床治療從脂蛋白分離術轉向藥物治療，正在重新定義治療方式，減少對侵入性且耗時的機械過濾的依賴。諸如ANGPTL3和MTP抑制劑等受體非依賴性療法的卓越療效，使得臨床醫生僅需藥物治療即可維持目標血脂水平，從而顯著減輕了許多患者每週接受分離術的負擔。這項轉變的驅動力在於新型藥物能夠繞過功能異常的LDL受體。根據2025年1月出版的《動脈粥狀硬化報告》（Current Atherosclerosis Reports），包括evinacumab和lomitapide在內的新型藥物療法，無論殘餘受體功能如何，均可將LDL膽固醇降低約50%，從而顯著減少臨床對體外脂質清除的需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：遺傳性高膽固醇症的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 藥物分類（他汀類藥物、膽固醇吸收抑制劑、PCSK9抑制劑、MTP抑制劑、ANGPTL3抑制劑）
  • 給藥途徑（口服、注射、鼻內）
  • 透過技術（CRISPR-Cas9、 RNA干擾、基於奈米顆粒的治療方法）
  • 銷售管道細分（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美純遺傳性高膽固醇症市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲純合子遺傳性性高膽固醇症市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區遺傳性高膽固醇症市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章 中東和非洲遺傳性高膽固醇症市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲純合子遺傳性高膽固醇症市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球純合子遺傳性性高膽固醇症市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Amgen Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi SA
• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Merck & Co., Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Homozygous Familial Hypercholesterolemia (HoFH) Market is projected to expand from USD 94.78 Million in 2025 to USD 111.01 Million by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 2.67%. HoFH is a severe genetic condition characterized by extremely high LDL cholesterol levels from birth, necessitating aggressive management to prevent premature cardiovascular events. The market's growth is primarily fueled by the introduction of innovative drug classes, such as ANGPTL3 inhibitors, which provide effective therapeutic solutions for patients who do not respond to conventional lipid-lowering treatments. Furthermore, the integration of advanced genetic screening into routine clinical practice is a crucial driver, enabling earlier intervention and supporting the adoption of these specialized pharmaceutical products.

However, the market faces a significant obstacle in accurately identifying the eligible patient population. Widespread underdiagnosis presents a critical barrier because the clinical presentation can vary, and specialized testing is not universally available. According to the World Heart Federation in 2024, less than 5% of individuals globally living with HoFH received an accurate and timely diagnosis. This substantial diagnostic gap severely limits the reach of available interventions and remains the primary challenge impeding broader market expansion.

Market Driver

The development of novel LDL-lowering biologics and small molecules is a primary catalyst for market growth, as pharmaceutical companies introduce advanced mechanisms to overcome the limitations of traditional statin therapies. New treatment modalities, including third-generation PCSK9 inhibitors and mRNA-based therapies, are rapidly progressing through clinical pipelines to address the severe cholesterol burden in patients with resistant profiles. For example, LIB Therapeutics announced in January 2025 the publication of Phase 3 study results evaluating the efficacy of the novel agent lerodalcibep in a cohort of 66 HoFH patients. These innovations not only expand the available therapeutic arsenal but also offer improved dosing convenience, thereby enhancing long-term treatment adherence for lifelong management.

Concurrently, favorable orphan drug designations and regulatory incentives are significantly boosting research and development investment within this specialized sector. Regulatory bodies are increasingly granting special statuses that reduce development costs and provide market exclusivity, encouraging biotechnology firms to target ultra-rare cardiovascular indications despite the limited patient pool. According to Fierce Pharma in January 2026, 57% of all novel drug approvals by the FDA in 2025 were designated as rare disease treatments, underscoring the intense industry focus fostered by these incentives. Such regulatory support is critical given the scarcity of the target population, with BioSpace reporting in January 2025 that the condition affects approximately 1 in 300,000 people worldwide. These incentives ensure that commercial interest remains sufficiently high to sustain the costly development of potentially curative interventions.

Market Challenge

The substantial difficulty in accurately identifying the eligible patient population represents a critical impediment to the growth of the Global Homozygous Familial Hypercholesterolemia (HoFH) Market. This widespread underdiagnosis creates a severe bottleneck, as novel therapeutics cannot be prescribed to individuals who remain undetected by the healthcare system. Consequently, the addressable market size is artificially suppressed, preventing manufacturers from realizing the full commercial value of advanced treatments like ANGPTL3 inhibitors. The significant disparity between the estimated prevalence of this genetic disorder and the actual number of diagnosed patients indicates a major loss of revenue potential for industry stakeholders.

This challenge is directly linked to inadequate testing protocols that result in the vast majority of cases going unnoticed. According to the Family Heart Foundation in 2025, only 11% of children in the United States between the ages of 9 and 21 had documented lipid screening. Such low screening rates confirm that most patients are missed during the optimal intervention window, thus remaining excluded from the pharmaceutical market. This systemic failure to capture the patient base significantly hampers market expansion and limits the reach of available therapies.

Market Trends

The regulatory expansion of biologics into pediatric patient populations is fundamentally broadening the addressable market by enabling intervention at the earliest stages of disease progression. Securing approvals for younger cohorts allows manufacturers to capture patients during the critical window for preventing irreversible vascular damage, rather than solely managing advanced disease in adults. This shift is exemplified by the label extension of ANGPTL3 inhibitors, which now cover infants and toddlers who previously lacked effective pharmacological options. For instance, Contemporary Pediatrics reported in September 2025 that the U.S. FDA approved the ANGPTL3 inhibitor evinacumab for children aged 1 to less than 5 years with HoFH, effectively establishing a new standard of care for this ultra-rare demographic.

Concurrently, the clinical transition from lipoprotein apheresis to pharmacological management is redefining the treatment landscape by reducing reliance on invasive, time-consuming mechanical filtration. The superior efficacy of receptor-independent therapies, such as ANGPTL3 and MTP inhibitors, empowers clinicians to maintain target lipid levels through medication alone, thereby alleviating the substantial burden of weekly apheresis sessions for many patients. This evolution is driven by the ability of novel agents to bypass defective LDL receptors; according to Current Atherosclerosis Reports in January 2025, new pharmacological regimens, including evinacumab and lomitapide, can reduce LDL cholesterol by approximately 50% irrespective of residual receptor function, significantly diminishing the clinical necessity for extracorporeal lipid removal.

Key Market Players

• Amgen Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.
• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Merck & Co., Inc.

Report Scope

In this report, the Global Homozygous Familial Hypercholesterolemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Homozygous Familial Hypercholesterolemia Market, By Drug Class

• Statins
• Cholesterol Absorption Inhibitors
• PCSK9 Inhibitors
• MTP Inhibitors
• ANGPTL3 Inhibitors

Homozygous Familial Hypercholesterolemia Market, By Route of Administration

• Oral
• Parenteral
• Nasal

Homozygous Familial Hypercholesterolemia Market, By Technology

• CRISPR-Cas9
• RNA Interference
• Nanoparticle-Based Therapies

Homozygous Familial Hypercholesterolemia Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Homozygous Familial Hypercholesterolemia Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Homozygous Familial Hypercholesterolemia Market.

Available Customizations:

Global Homozygous Familial Hypercholesterolemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Homozygous Familial Hypercholesterolemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Statins, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, MTP Inhibitors, ANGPTL3 Inhibitors)
  • 5.2.2. By Route of Administration (Oral, Parenteral, Nasal)
  • 5.2.3. By Technology (CRISPR-Cas9, RNA Interference, Nanoparticle-Based Therapies)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Homozygous Familial Hypercholesterolemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Route of Administration
  • 6.2.3. By Technology
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Homozygous Familial Hypercholesterolemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Technology
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Homozygous Familial Hypercholesterolemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Technology
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Homozygous Familial Hypercholesterolemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Technology
      • 6.3.3.2.4. By Distribution Channel

7. Europe Homozygous Familial Hypercholesterolemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Route of Administration
  • 7.2.3. By Technology
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Homozygous Familial Hypercholesterolemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Technology
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Homozygous Familial Hypercholesterolemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Technology
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Homozygous Familial Hypercholesterolemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Technology
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Homozygous Familial Hypercholesterolemia Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Technology
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Homozygous Familial Hypercholesterolemia Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Technology
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Homozygous Familial Hypercholesterolemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Route of Administration
  • 8.2.3. By Technology
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Homozygous Familial Hypercholesterolemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Technology
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Homozygous Familial Hypercholesterolemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Technology
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Homozygous Familial Hypercholesterolemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Technology
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Homozygous Familial Hypercholesterolemia Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Technology
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Homozygous Familial Hypercholesterolemia Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Technology
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Homozygous Familial Hypercholesterolemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Route of Administration
  • 9.2.3. By Technology
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Homozygous Familial Hypercholesterolemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Technology
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Homozygous Familial Hypercholesterolemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Technology
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Homozygous Familial Hypercholesterolemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Technology
      • 9.3.3.2.4. By Distribution Channel

10. South America Homozygous Familial Hypercholesterolemia Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Route of Administration
  • 10.2.3. By Technology
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Homozygous Familial Hypercholesterolemia Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Technology
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Homozygous Familial Hypercholesterolemia Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Technology
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Homozygous Familial Hypercholesterolemia Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Technology
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Homozygous Familial Hypercholesterolemia Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Amgen Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Regeneron Pharmaceuticals, Inc.
• 15.3. Sanofi S.A.
• 15.4. Pfizer Inc.
• 15.5. Novartis AG
• 15.6. Eli Lilly and Company
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. Bristol-Myers Squibb Company
• 15.9. AstraZeneca plc
• 15.10. Merck & Co., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer